1. In this randomized controlled trial involving patients with disease progression during first-line treatment for breast cancer, giredestrant plus everolimus ...
1. In patients with ER-positive, HER2-negative advanced breast cancer who developed an ESR1 mutation during first-line aromatase inhibitor plus CDK4/6 ...
Click to read this study in The Lancet Oncology.
1. Median progression free survival was longer in the fulvestrant and palbociclib group compared to the aromatase inhibitor plus palbociclib ...
Monthly plan selected: $4.99 /month.
3-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
Already a member? Sign in
